Interview with Cassandra Duarte, MD: CAR-T for CNS Lymphoma

Interview with Ellen Velisek, RN, BSN, OCN: Patient Coordination Following CAR T-Cell Therapy

Interview with Ellen Velisek, RN, BSN, OCN: Preparing Patients for CAR T-Cell Therapy

Welcome to the CAR T-Cell Therapy Resource Center! Here you’ll find current information, news items, highlights from the literature, case studies, and other resources that focus on CAR T-cell therapies and the advanced practitioner’s role in delivering high-quality care to our patients. If you have any feedback or questions, please contact jadpro-editor@conexiant.com.

Meredith Beaton, MSN, AGACNP-BC Assistant Professor of Medicine
Associate Vice Chair for APP Development & Mentorship
Medical Director, Inpatient BMT Program
University of Colorado School of Medicine

CancerCare

ASH-ASTCT COVID-19 Vaccination for HCT and CAR T Cell Recipients: Frequently Asked Questions

Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

Practical Guidance for the Diagnosis and Management of Secondary Hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees

Chimeric antigen receptor T-Cell therapy in autoimmune disorders: An expert panel opinion from the American Society for Transplantation and Cellular Therapy

Prospects of chimeric antigen receptor T-Cell therapy in myelofibrosis: From immunopathogenesis to therapeutic strategies

Exploratory Research in Clinical and Social Pharmacy

Transitions of care between pediatric onco-hematology and intensive care units: An exploratory study of healthcare professionals' perceptions and practices in medication management

CAR T-Cell Therapy Resource Center

Interview with Cassandra Duarte, MD: CAR-T for CNS Lymphoma

CancerCare

ASH-ASTCT COVID-19 Vaccination for HCT and CAR T Cell Recipients: Frequently Asked Questions

Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

Practical Guidance for the Diagnosis and Management of Secondary Hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees

Informational Modules for US Healthcare Providers

Transplantation and Cellular Therapy

Long-Term follow-up of CD19 CAR-T for R/R B-NHL: Ki-67 as a prognostic factor for sustained remission

Transplantation and Cellular Therapy

Chimeric antigen receptor T-Cell therapy in autoimmune disorders: An expert panel opinion from the American Society for Transplantation and Cellular Therapy

Nature Medicine

Tumor inflammation-associated neurotoxicity

Cancers

Prospects of chimeric antigen receptor T-Cell therapy in myelofibrosis: From immunopathogenesis to therapeutic strategies

Exploratory Research in Clinical and Social Pharmacy

Transitions of care between pediatric onco-hematology and intensive care units: An exploratory study of healthcare professionals' perceptions and practices in medication management

Bone Marrow Transplantation

Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma

Cytotherapy

Impact of blinatumomab and inotuzumab exposure on apheresis composition for CAR T in patients with B-cell acute lymphoblastic leukemia

Critical Reviews in Oncology/Hematology

In vivo generation of CAR-T cells: Current obstacles, strategic solutions, and clinical translation

Frontiers in Oncology

Safety and efficacy of CAR T-cell therapy in central nervous system lymphoma: A systematic review and meta-analysis

Nature Medicine

In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: A phase 1 study

Identifying and Managing CAR T-Associated Hemophagocytic Lymphohistiocytosis Following Dual-Targeted CAR T-Cell Therapy

Prophylactic Tocilizumab in Selected High-Risk or Outpatient CAR-T Populations

Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy in a Patient With Multiple Myeloma

Fast Facts #12: BCMA Targets